Literature DB >> 28176241

Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials.

Pierfrancesco Franco1, Francesca Arcadipane2, Paolo Strignano3, Rosella Spadi4, Elisabetta Trino2, Stefania Martini2, Giuseppe Carlo Iorio2, Maria Antonietta Satolli5, Mario Airoldi6, Renato Romagnoli3, Michele Camandona7, Umberto Ricardi2.   

Abstract

Adenocarcinomas of the lower oesophagus and gastro-oesophageal junction are a complex clinico-pathological setting. Multimodality therapy is considered mandatory in most disease presentations. Nevertheless, the most appropriate treatment package has yet to be established. We herein summarize the evidence derived from randomized phase III trials on pre-operative treatments in this oncological scenario.

Entities:  

Keywords:  Adenocarcinoma; Gastro-oesophageal junction; Neoadjuvant chemotherapy; Oesophageal cancer; Pre-operative chemo-radiation; Radiotherapy

Mesh：

Year:  2017        PMID： 28176241     DOI： 10.1007/s12032-017-0898-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  27 in total

Review 1.  Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction.

Authors:  M C C M Hulshof; H W M van Laarhoven
Journal:  Best Pract Res Clin Gastroenterol       Date:  2016-06-25       Impact factor: 3.043

2.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

4.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

5.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

6.  Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.

Authors:  K Nygaard; S Hagen; H S Hansen; R Hatlevoll; R Hultborn; A Jakobsen; M Mäntyla; H Modig; E Munck-Wikland; B Rosengren
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

7.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group).

Authors:  S J Arnott; W Duncan; M Gignoux; D J Girling; H S Hansen; B Launois; K Nygaard; M K Parmar; A Roussel; G Spiliopoulos; L A Stewart; J F Tierney; W Mei; Z Rugang
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038

Review 9.  Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting.

Authors:  Pierfrancesco Franco; Alba Fiorentino; Francesco Dionisi; Michele Fiore; Silvia Chiesa; Stefano Vagge; Francesco Cellini; Luciana Caravatta; Mario Tombolini; Fiorenza De Rose; Icro Meattini; Gianluca Mortellaro; Giuseppina Apicella; Lorenza Marino; Daniela Greto
Journal:  Tumori       Date:  2016-07-02       Impact factor: 2.098

10.  A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Authors:  F Klevebro; G Alexandersson von Döbeln; N Wang; G Johnsen; A-B Jacobsen; S Friesland; I Hatlevoll; N I Glenjen; P Lind; J A Tsai; L Lundell; M Nilsson
Journal:  Ann Oncol       Date:  2016-01-17       Impact factor: 32.976
View more
  4 in total

1.  Radiotherapy treatment strategies for squamous cell carcinoma of the cervical oesophagus: moving toward better outcomes.

Authors:  Pierfrancesco Franco; Francesca Arcadipane; Paolo Strignano; Renato Romagnoli; Umberto Ricardi
Journal:  Ann Transl Med       Date:  2017-11

2.  The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.

Authors:  Emily Z Keung; Esosa U Ukponmwan; Alexandria P Cogdill; Jennifer A Wargo
Journal:  Ann Surg Oncol       Date:  2018-03-02       Impact factor: 5.344

3.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

4.  Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients.

Authors:  Stefania Martini; Francesca Arcadipane; Paolo Strignano; Rosella Spadi; Viviana Contu; Christian Fiandra; Riccardo Ragona; Giorgia Catalano; Maria Antonietta Satolli; Michele Camandona; Renato Romagnoli; Umberto Ricardi; Pierfrancesco Franco
Journal:  Med Oncol       Date:  2018-10-04       Impact factor: 3.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.